subscribeSubscribe
price-trendAsk Us
Karyopharm reports interim data from eltanexor Phase I/II study

Karyopharm reports interim data from eltanexor Phase I/II study
CLINICAL TRIALS ARENA
04 May 2023
Share Share
Karyopharm Announces Presentation Data from pH 2 Study of Single-Agent Eltanexor

Karyopharm Announces Presentation Data from pH 2 Study of Single-Agent Eltanexor
BUSINESSWIRE
03 May 2023
Share Share
Karyopharm Receives ODD from FDA for Eltanexor in Myelodysplastic Syndromes

Karyopharm Receives ODD from FDA for Eltanexor in Myelodysplastic Syndromes
PRNEWSWIRE
24 Jan 2022
Share Share
Karyopharm Announces Dosing of First Patient in a Phase 2 Stud

Karyopharm Announces Dosing of First Patient in a Phase 2 Stud
Brian Park PRESS RELEASE
21 Oct 2021
Share Share
Karyopharm Therapeutics Announces Updated Data of Eltanexor

Karyopharm Therapeutics Announces Updated Data of Eltanexor
PRNEWSWIRE
09 Jun 2021
Share Share
Approval of Ph I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation

Approval of Ph I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation
PRNEWSWIRE
25 Nov 2020
Share Share
Karyopharm & Antengene Sign Exclusive License Agreement Selinexor & KPT-9274

Karyopharm & Antengene Sign Exclusive License Agreement Selinexor & KPT-9274
NASADQ
24 May 2018
Share Share